Skip to main content
. 2019 May 26;27(1):283–293. doi: 10.1007/s40199-019-00274-3

Fig. 5.

Fig. 5

IL-1α (a) and IL-8 (b) release by negative control (SMM), positive control (Fenolia® Eudermal Cream 15), pro-inflammatory positive controls (PBS 1X and LPS 100 μg/mL, respectively), anti-inflammatory reference treatments (PBS 1X or LPS 100 μg/mL + Dexamethasone 10 μM) and HT-based formulation treatments (PBS 1X or LPS 100 μg/mL + Fenolia® Eudermal Cream 15) for 24 h. *P ≤ 0.001 vs pro-inflammatory positive control (PBS 1X and LPS 100 μg/mL, respectively)